Skip to content
Open access · US-GOV via ClinicalTrials.gov Clinical trial

Modulation of Beta-amyloid Levels in CSF and Plasma by GSK933776 in Patients With Mild Alzheimer's Disease or Mild Cognitive Impairment

Authors not listed

GlaxoSmithKline · 2010

Abstract

Modulation of beta-amyloid levels in CSF and plasma by GSK933776 in patients with mild Alzheimer's disease or mild cognitive impairment

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-11-14 MST

Cite this

APA
Anonymous. (2010). Modulation of Beta-amyloid Levels in CSF and Plasma by GSK933776 in Patients With Mild Alzheimer's Disease or Mild Cognitive Impairment. <em>GlaxoSmithKline</em>. https://clinicaltrials.gov/study/NCT01424436
Vancouver
Anonymous. Modulation of Beta-amyloid Levels in CSF and Plasma by GSK933776 in Patients With Mild Alzheimer's Disease or Mild Cognitive Impairment. GlaxoSmithKline. 2010.
BibTeX
@misc{anon2010Modula, title = {Modulation of Beta-amyloid Levels in CSF and Plasma by GSK933776 in Patients With Mild Alzheimer's Disease or Mild Cognitive Impairment}, author = {Anonymous}, journal = {GlaxoSmithKline}, year = {2010}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings